Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem(TM) ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Stock Information for Creative Medical Technology Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Creative Medical Technology Holdings Inc.

Creative Medical Technology Holdings Provides Corporate Update
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
Creative Medical Technology Holdings Provides Corporate Update
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem(TM) (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?
The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.